PMID: 2123720Dec 4, 1990Paper

Putative mechanisms of action of probucol on high-density lipoprotein apolipoprotein A-I and its isoproteins kinetics in rabbits

Biochimica Et Biophysica Acta
H YingK Arakawa

Abstract

Probucol is a widely prescribed lipid-lowering agent, the major effects of which are to lower cholesterol in both low- and high-density lipoproteins (LDL and HDL, respectively). The mechanism of action of probucol on HDL apolipoprotein (apo) A-I kinetics was investigated in rabbits, with or without cholesterol feeding. 125I-labeled HDL was injected intravenously, and blood samples were taken periodically for 6 days. Kinetic parameters were calculated from the apo A-I-specific radioactivity decay curves. Fractional catabolic rate (FCR) and synthetic rate (SR) of apo A-I in rabbits fed a normal chow and normal chow with 1% probucol were similar. Apo A-I FCR of the rabbits fed 0.5% cholesterol was significantly increased but there were no changes in SR, compared to findings in the normal chow-fed group. Apo A-I FCR of the rabbits fed 1% probucol with 0.5% cholesterol (both 1 month and 2 months) was significantly increased compared to findings in rabbits fed the normal chow as well as 0.5% cholesterol diet group, while SR of apo A-I was significantly reduced in the former groups. Kinetics at 1 month after discontinuation of 1% probucol (under cholesterol feeding) showed a similar FCR of HDL-apo A-I to that of the rabbits fed 0.5% c...Continue Reading

References

Dec 1, 1976·Clinical Pharmacology and Therapeutics·A F SalelD T Mason
Oct 1, 1977·The Journal of Clinical Investigation·C B BlumM Berman
Jul 25, 1978·Biochimica Et Biophysica Acta·R S KushwahaJ Engblom
Jul 1, 1989·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·Y NaganoC Kawai
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·T KitaC Kawai
Jun 27, 1986·The American Journal of Cardiology·A YamamotoB Kishino
Feb 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·G GhiselliB C Sherrill
May 1, 1985·The Journal of Clinical Investigation·K SakuM L Kashyap
May 1, 1984·Metabolism: Clinical and Experimental·K SakuM L Kashyap
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON
Feb 1, 1958·The Journal of Clinical Investigation·D GITLINC A JANEWAY
Jul 5, 1958·Nature·A S McFARLANE

❮ Previous
Next ❯

Citations

Jan 1, 1993·European Journal of Clinical Pharmacology·K SakuK Arakawa
Jan 1, 1994·Pharmacology & Therapeutics·G FranceschiniL Calabresi
Sep 1, 1993·European Journal of Clinical Investigation·R LiuK Arakawa
Sep 5, 2014·F1000Research·Norman E Miller
Oct 12, 2013·Journal of Animal Physiology and Animal Nutrition·K KayaT Güldür
Jun 28, 2001·Journal of Atherosclerosis and Thrombosis·B ZhangT Ohta

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.